Pneumococcal Conjugate Vaccine Safety in Elderly Adults

BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) were both recommended to adults aged ≥65 years. The study examines adults ≥65 years for risk of adverse events (AEs) requiring medical attention following vaccination with...

Descripción completa

Detalles Bibliográficos
Autores principales: Tseng, Hung Fu, Sy, Lina S, Qian, Lei, Liu, In-Lu A, Mercado, Cheryl, Lewin, Bruno, Tartof, Sara Y, Nelson, Jennifer, Jackson, Lisa A, Daley, Matthew F, Weintraub, Eric, Klein, Nicola P, Belongia, Edward, Liles, Elizabeth G, Jacobsen, Steven J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016414/
https://www.ncbi.nlm.nih.gov/pubmed/29977960
http://dx.doi.org/10.1093/ofid/ofy100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016414/
https://www.ncbi.nlm.nih.gov/pubmed/29977960
http://dx.doi.org/10.1093/ofid/ofy100

Ejemplares similares